文献

J-GLOBAL ID：202202239578305064   整理番号：22A1152191

生物起源リボソーム蛋白質による吸入mRNAナノ製剤はブレオマイシン誘発マウスモデルにおける確立肺線維症を逆転させる【JST・京大機械翻訳】

Inhaled mRNA Nanoformulation with Biogenic Ribosomal Protein Reverses Established Pulmonary Fibrosis in a Bleomycin-Induced Murine Model

著者 (27件)： Zhang Rui (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Jing Weiqiang (Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Chen Chen (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Zhang Shengchang (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Abdalla Mohnad (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Sun Peng (Shandong University of Traditional Chinese Medicine, Jinan, 250355, China) ,  Wang Ganyu (Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  You Wenjie (Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250021, China) ,  Yang Zhenmei (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Zhang Jing (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Tang Chunwei (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Du Wei (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Liu Ying (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Li Xiaoxun (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Liu Jitian (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  You Xiaona (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Hu Huili (Experimental Teratology, Ministry of Education and Department of Molecular Medicine and Genetics, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Cai Lei (Shandong Provincial Key Laboratory of Biosensors, Biology Institute, Qilu University of Technology, Jinan, 250103, China) ,  Xu Fengbo (Yinfeng Biological Group Co., LTD., Jinan, 250102, China) ,  Dong Baixiang (Yinfeng Biological Group Co., LTD., Jinan, 250102, China) ,  Liu Minglu (Bellastem Biotechnology Limited, Gaomi, 261500, China) ,  Qiang Bangming (Bellastem Biotechnology Limited, Gaomi, 261500, China) ,  Sun Yanhua (Shandong Provincial Key Laboratory of Microparticles Drug Delivery Technology, Qilu Pharmaceutical Co., LtD, Jinan, 250100, China) ,  Yu Gongchang (Neck-Shoulder and Lumbocrural Pain Hospital, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250012, China) ,  Wu Jibiao (Shandong University of Traditional Chinese Medicine, Jinan, 250355, China) ,  Zhao Kun (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China) ,  Jiang Xinyi (NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China)
資料名： Advanced Materials  (Advanced Materials)
巻： 34  号： 14  ページ： e2107506  発行年： 2022年 
JST資料番号： W0001A  ISSN： 0935-9648  CODEN： ADVMEW  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： ドイツ (DEU)  言語： 英語 (EN)

抄録/ポイント： 治療選択肢の少ない致死的呼吸器疾患である特発性肺線維症(IPF)は,肺胞上皮細胞(AEC)に対する反復微小損傷により生じ,細胞外マトリックス(ECM)の圧倒的な沈着により進行し,最終的に線維症瘢痕を生じ,肺胞構造を破壊する。ここでは,吸入リボソーム蛋白質に基づくmRNAナノ製剤を,肺内ECMをクリアリングし,破壊した肺胞上皮を再上皮化するため報告し,これにより,IPFで確立された線維症病巣を反転した。ナノ製剤は,PEG化遮蔽シェルを有する二機能性ペプチド修飾コロナとケラチン細胞成長因子(KGF)のリボソーム蛋白質凝縮mRNAコアにより順次組み立てられる。ネブライザーを介して吸入すると,マイクロドロップにより運ばれたナノ製剤は肺胞に沈着し,線維性病巣に浸透し,外側KGFはマトリックスメタロプロテイナーゼ2(MMP2)誘発後に脱離する。RGDモチーフグラフト化コアは,その後,mRNAの細胞内デリバリーのためにインテグリン上昇細胞を曝露し,特異的に標的化する。特に,ナノ製剤の反復吸入は,ブレオマイシン誘導マウスモデルの肺機能を相乗的に改善する,MMP13の病巣内発現およびKGFにより仲介される肺胞再上皮化を促進することにより,局所コラーゲンのクリアランスを加速する。したがって,本研究は代替mRNA吸入デリバリー戦略を提供し,IPFの治療に対する大きな可能性を示す。Copyright 2022 Wiley Publishing Japan K.K. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 凝縮 ,  脱着 ,  *mRNA ,  *吸入 ,  コラーゲン ,  肺胞 ,  *ブレオマイシン ,  *肺線維症 ,  ターゲティング ,  瘢痕 ,  *線維症 ,  細胞外マトリックス ,  インテグリン
準シソーラス用語： 特発性肺線維症 ,  PEG化 , 【Automatic Indexing@JST】

著者キーワード (5件)： カチオン性リボソーム蛋白質 ,  特発性肺線維症 ,  吸入 ,  メッセンジャーRNA ,  線維性病巣の逆転

分類 (2件)： 物理化学一般その他  (CB01030T) ,  固-固界面  (CB12060M)

タイトルに関連する用語 (10件)： 生物起源 ,  リボソーム蛋白質 ,  吸入 ,  mRNA ,  ナノ製剤 ,  ブレオマイシン ,  誘発 ,  マウスモデル ,  肺線維症 ,  逆転